论文部分内容阅读
作为未来的“黄金”产业之一,生物医药无疑是战略性新兴产业中的“老大哥”。在许多地区刚刚起步,摩拳擦掌之际,莱山早已先行一步,抢占了生物医药产业发展的制高点。与莱山区“同龄”的绿叶制药集团,从1994年建厂起就瞄准了生物医药这一领域。1994年建厂,1998年产值过亿,2004年在新加坡上市,2006年完成第一次收购,2010年进军生物技术领域,2013年多个产品在美国临床研究取得阶段性进展,2014年在香
As one of the future “gold ” industries, biomedicine is undoubtedly the “big brother” in the strategic emerging industries. In many areas just started, gearing up on the occasion, Laishan has already taken the first step, to seize the commanding height of the development of bio-pharmaceutical industry. With Lvshan District “same age ” Green Leaf Pharmaceutical Group, since 1994 set up factories aimed at the field of biomedicine. The plant was established in 1994 with a production value of more than 100 million in 1998 and was listed in Singapore in 2004. The first acquisition was completed in 2006 and the biotechnology field in 2010. In 2013, several products made phased progress in clinical research in the United States. In 2014,